Search Results
Università Cattolica del Sacro Cuore, Rome, Italy
ENETS Center of Excellence, Neuroendocrine Tumour (NET) Center, Rome, Italy
Search for other papers by Guido Rindi in
Google Scholar
PubMed
ENETS Center of Excellence, Neuroendocrine Tumour (NET) Center, Rome, Italy
Search for other papers by Frediano Inzani in
Google Scholar
PubMed
types or, perhaps, neuroendocrine-committed cells do transform, generating neoplasms. Neoplasms made by cells with a neuroendocrine phenotype are today defined as neuroendocrine neoplasia (NEN). Similar to neuroendocrine cells, NEN are observed in pure
Search for other papers by Günter Klöppel in
Google Scholar
PubMed
includes the tumours that generate steroid hormones. The tumours of the first group are called neuroendocrine neoplasms (NENs) because of the marker proteins that they share with the neural cell system. These markers are synaptophysin and neuron
Search for other papers by Fritz-Line Vélayoudom-Céphise in
Google Scholar
PubMed
Search for other papers by Pierre Duvillard in
Google Scholar
PubMed
Search for other papers by Lydia Foucan in
Google Scholar
PubMed
Search for other papers by Julien Hadoux in
Google Scholar
PubMed
Search for other papers by Cecile N Chougnet in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by David Malka in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by Joël Guigay in
Google Scholar
PubMed
Search for other papers by Diane Goere in
Google Scholar
PubMed
Search for other papers by Thierry Debaere in
Google Scholar
PubMed
Search for other papers by Caroline Caramella in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by David Planchard in
Google Scholar
PubMed
Search for other papers by Dominique Elias in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Oncology, Pathology, Department of Biostatistics and Epidemiology, Departments of Gastroenterology, Thoracic Oncology, Digestive Surgery, Medical Imaging, Faculté de Médecine Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Search for other papers by Michel Ducreux in
Google Scholar
PubMed
Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed
Search for other papers by Eric Baudin in
Google Scholar
PubMed
Introduction Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are rare tumors defined by the expression of specific diagnostic biomarkers ( Baudin 2007 , Modlin et al . 2008 , Yao et al . 2008 ). Their prognosis is best characterized by
Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed
Search for other papers by Gregory A Kaltsas in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by Eleftherios Chatzellis in
Google Scholar
PubMed
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NENs), previously named ‘carcinoid’ tumours, most frequently occur in the gastrointestinal (GI) tract (54.5%) and have been an area of ongoing interest in the field of many different disciplines including
Department of Clinical Sciences, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
Search for other papers by Grace Kong in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
-term toxicity. 177 Lu-DOTA-octreotate (LuTathera) has recently obtained regulatory approval for patients with progressive metastatic grade 1–2 GEP NET. High-grade gastroenteropancreatic neuroendocrine neoplasms: NET G3 and NEC Gastroenteropancreatic
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Andreas Venizelos in
Google Scholar
PubMed
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
Search for other papers by Hege Elvebakken in
Google Scholar
PubMed
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Oleksii Nikolaienko in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Wei Deng in
Google Scholar
PubMed
Search for other papers by Inger Marie B Lothe in
Google Scholar
PubMed
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Geir Olav Hjortland in
Google Scholar
PubMed
Department of Medical Radiation Physics, Lund University, Lund, Sweden
Search for other papers by Anna Sundlöv in
Google Scholar
PubMed
Search for other papers by Johanna Svensson in
Google Scholar
PubMed
Search for other papers by Harrish Garresori in
Google Scholar
PubMed
Search for other papers by Christian Kersten in
Google Scholar
PubMed
Department of Oncology, St.Olavs Hospital, Trondheim, Norway
Search for other papers by Eva Hofsli in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Search for other papers by Sönke Detlefsen in
Google Scholar
PubMed
Search for other papers by Merete Krogh in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Stian Knappskog in
Google Scholar
PubMed
Introduction High-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are defined by the presence of neuroendocrine phenotype and a high proliferation rate (Ki-67 > 20%). The HG NEN entity consists of well
NHS Nightingale Hospital London, London, UK
Search for other papers by Ashley K Clift in
Google Scholar
PubMed
Search for other papers by Andrea Frilling in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NEN) represent a heterogeneous class of tumours that arise from nigh ubiquitously dispersed neuroendocrine cells, which may be stratified into clinically meaningful sub-groups on the basis of their
Maimonides Institute for Biomedical Research of Cordoba (IMIBIC); Reina Sofia University Hospital, Córdoba, Spain
Search for other papers by Aura D Herrera-Martínez in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Search for other papers by María A Gálvez Moreno in
Google Scholar
PubMed
Search for other papers by Justo P Castaño in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NENs) represent a heterogeneous group of rare neoplasms, which originate from enterochromaffin cells that are located throughout the whole body. NENs located in the gastrointestinal tract and pancreas are
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
Search for other papers by Elia Guadagno in
Google Scholar
PubMed
Search for other papers by Erika Messina in
Google Scholar
PubMed
Search for other papers by Fabio Lo Calzo in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by NIKE Group in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NENs) are well known to display a wide heterogeneity as concerns histopathology, clinical presentation, treatment and prognosis. Despite their rarity, NENs have drawn a lot of attention due to the newly
Search for other papers by Jennifer R Eads in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Tim Asmis in
Google Scholar
PubMed
Search for other papers by Andrew M Bellizzi in
Google Scholar
PubMed
Search for other papers by Emily K Bergsland in
Google Scholar
PubMed
Search for other papers by Arvind Dasari in
Google Scholar
PubMed
Search for other papers by Ghassan El-Haddad in
Google Scholar
PubMed
Search for other papers by Michael Frumovitz in
Google Scholar
PubMed
Search for other papers by Joshua Meyer in
Google Scholar
PubMed
Search for other papers by Erik Mittra in
Google Scholar
PubMed
Search for other papers by Sten Myrehaug in
Google Scholar
PubMed
Search for other papers by Eric Nakakura in
Google Scholar
PubMed
Search for other papers by Nitya Raj in
Google Scholar
PubMed
Search for other papers by Heloisa P Soares in
Google Scholar
PubMed
Search for other papers by Brian Untch in
Google Scholar
PubMed
Search for other papers by Namrata Vijayvergia in
Google Scholar
PubMed
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Introduction High-grade neuroendocrine neoplasms (NENs) constitute a rare disease entity and account for approximately 10% of all NENs. Given their rarity, there is a paucity of prospective data to guide the optimal diagnosis and management of